Leader Capital Markets VP research Alon Glazer says in response to today's profit warnings by Bank Leumi and First International Bank of Israel that the warnings were
Sabina Podval reiterated her "Outperform" recommendation for Teva with a target price of $49. "Now is the best time to substantially increase a position in the paper"